Novo Nordisk
2011-11-07T14:33:02Z
2011-11-07T14:33:02Z
Novo Nordisk A/S: DegludecPlus provides superior glycaemic control compared to insulin glargine in a phase 3a trial in Japanese people with type 2 diabetes
Novo Nordisk today announced clinical results from a 26-week phase 3a treat-to-target study comparing DegludecPlus, a soluble combination of ultra-long-acting insulin degludec and insulin aspart, to insulin glargine in Japanese people with type 2 diabetes inadequately controlled on oral antidiabetic drugs. This is the 18th announced phase 3a study in the Degludec and DegludecPlus clinical trial development programme.
Further information
| Media: | Investors: |
| Katrine Sperling | Klaus Bülow Davidsen |
| Tel: (+45) 4442 6718 | Tel: (+45) 4442 3176 |
| krsp@novonordisk.com | klda@novonordisk.com |
| Frank Daniel Mersebach | |
| Tel: (+45) 4442 0604 | |
| fdni@novonordisk.com | |
| Lars Borup Jacobsen | |
| Tel: (+45) 3075 3479 | |
| lbpj@novonordisk.com | |
| In North America: | |
| Ambre Morley | Jannick Lindegaard |
| Tel: (+1) 609 216 5240 | Tel: (+1) 609 786 4575 |
| abmo@novonordisk.com | jlis@novonordisk.com |
Company Announcement no 70 / 2011